摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3β,14α,16α)-(+/-)-14,15-dihydro-20,21-dinoreburnamenin-14-ol

中文名称
——
中文别名
——
英文名称
(3β,14α,16α)-(+/-)-14,15-dihydro-20,21-dinoreburnamenin-14-ol
英文别名
(15S,17S,19R)-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-ol
(3β,14α,16α)-(+/-)-14,15-dihydro-20,21-dinoreburnamenin-14-ol化学式
CAS
——
化学式
C17H20N2O
mdl
——
分子量
268.359
InChiKey
KOIGYXJOGRVNIS-KNXALSJPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    20
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    28.4
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (1R,12bS)-(1,2,3,4,6,7,12,12b-Octahydro-indolo[2,3-a]quinolizin-1-yl)-acetonitrile 在 盐酸4-二甲氨基吡啶二异丁基氢化铝 作用下, 以 四氢呋喃二氯甲烷甲苯 为溶剂, 反应 10.0h, 生成 (3β,14α,16α)-(+/-)-14,15-dihydro-20,21-dinoreburnamenin-14-ol
    参考文献:
    名称:
    Total Synthesis of (±)-Deethyleburnamonine and Vindeburnol (RU 24722) with the Corresponding Nitriles as Starting Material
    摘要:
    Cyclisation occurred during base treatment of cis-nitrile (5). The resulting new imine (6) was converted into the therapeutically important deethyleburnamonine (4). Total synthesis of vindeburnol (RU 24722) (3), another important drug, was achieved in one step starting from the trans-nitrile (9).
    DOI:
    10.3987/com-99-8486
点击查看最新优质反应信息

文献信息

  • Stereoselective total synthesis of (±)-vindeburnol and (±)-16-<i>epi</i>-vindeburnol
    作者:Xiangtao Chen、Lei Yu、Huijing Wang、Wen Zhang、Pei Tang、Fener Chen
    DOI:10.1039/d1cc04980a
    日期:——
    A concise stereoselective total synthesis of (±)-vindeburnol and its epimer (±)-16-epi-vindeburnol is presented. This synthetic work features the utilization of Baeyer–Villiger oxidation to install different types of lactone substrate, and a sequence of aminolysis, aldimine condensation and acyl-Pictet–Spengler to deliver the crucial trans-fused indoloquinolizidine scaffold with high-level diastereocontrol
    提出了 (±)-vindeburnol 及其差向异构体 (±) -16- epi- vindeburnol的简洁立体选择性全合成。这项合成工作的特点是利用 Baeyer-Villiger 氧化来安装不同类型的内酯底物,以及一系列氨解、醛亚胺缩合和酰基-Pictet-Spengler 以提供具有高水平非对映控制的关键反式融合吲哚并喹唑啉支架。
  • Easy functiohalination of C(17) in the desethylebunnamonine series
    作者:Reija Jokela、Mauri Lounasmaa
    DOI:10.1016/0040-4020(89)80057-2
    日期:1989.1
    A new and interesting C(17)-functionalized desethyleburnamonine derivative was synthesized. When subjected to different reducing conditions this dicarbonyl compound afforded compounds .
    合成了一种新的和有趣的C(17)-官能化的乙基乙基氨氮衍生物。当经受不同的还原条件时,该二羰基化合物提供了化合物。
  • Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders
    申请人:Pujol Jean-Francois
    公开号:US20070155769A1
    公开(公告)日:2007-07-05
    The invention relates to a novel therapeutic use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment of serious depression in humans, particularly for the treatment of a patients resistant to conventional anti-depressant treatments and for treatment of sleep/waking cycle disorders.
    该发明涉及使用14,15-二氢-20,21-二去氧热巴曼宁-14-醇的新型治疗用途,用于治疗人类严重抑郁症,特别是用于治疗对传统抗抑郁治疗方法有抵抗性的患者以及治疗睡眠/清醒周期障碍。
  • Produits optiquement actifs de dérivés de 20,21-dinoréburnaménine, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
    申请人:ROUSSEL-UCLAF
    公开号:EP0317426B1
    公开(公告)日:1993-06-02
  • AKTOGU, NURGUM;CLEMENCE, FRANCOIS;OBERLANDER, CLAUDE
    作者:AKTOGU, NURGUM、CLEMENCE, FRANCOIS、OBERLANDER, CLAUDE
    DOI:——
    日期:——
查看更多

同类化合物

长春考酯 长春曲尔 铁屎米酮N氧化物 铁屎米酮 苦木西碱Q 温可纳特 9-羟基铁屎米酮 9-甲氧基铁屎米酮N氧化物 9-甲氧基-6H-吲哚并[3,2,1-De][1,5]萘啶-6-酮 9,10-二甲氧基铁屎米酮 7,14-二苯基二吲哚并[3,2,1-去:3',2',1'-ij][1,5]萘啶-6,13-二酮 5-羟基-6-铁屎米酮 5-羟基-4-甲氧基铁屎米酮 5-甲氧基铁屎米酮 4,5-二甲氧基铁屎米酮 11-羟基-6H-吲哚并[3,2,1-de][1,5]萘啶-6-酮 11-甲基-20,21-二去甲埃那美宁 10-羟基-6H-吲哚并[3,2,1-de][1,5]萘啶-6-酮 1-羟基-6-铁屎米酮 1,2,3,3a,4,5-六氢铁屎米酮 1,2,3,3a,4,5-六氢-3-甲基-6H-吲哚并(3,2,1-de)(1,5)萘啶-6-酮单甲烷磺酸盐 1,2,3,3a,4,5-六氢-3-乙基-6H-吲哚并(3,2,1-de)(1,5)萘啶-6-酮 (3S,16S)-17alpha,21-环氧-14,15-二氢-14alpha-羟基-12-甲氧基埃那美宁-14-羧酸甲酯 4-[2-[[(15S,17R,19R)-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-yl]oxy]ethyl]morpholine (+/-)-deethyleburnamine (+/-)-16-epideethyleburnamine 3-butyl-4-methoxycanthin-5,6-dione 3-butyl-9-methoxycanthin-5,6-dione 4-methoxy-5-propoxycanthinone 4-methoxy-5-sec-butoxycanthinone 4-methoxy-5-butoxycanthinone 4-ethyl-3-methylcanthin-5,6-dione 10-bromo-4-methoxy-3-methylcanthin-5,6-dione 8,10-dibromo-3-methylcanthin-5,6-dione 4-methoxy-5-(2-bromoethoxy)canthinone 7,14-bis(5'-bromo-3'-dodecyl-[2,2'-bithiophen]-5-yl)diindolo[3,2,1-de:3',2',1'-ij][1,5]naphthyridine-6,13-dione 7,14-bis(5'-hexyl-[2,2'-bithiophen]-5-yl)diindolo[3,2,1-de:3',2',1'-ij][1,5]naphthyridine-6,13-dione 7,14-bis(3'-dodecyl-[2,2'-bithiophen]-5-yl)diindolo[3,2,1-de:3',2',1'-ij][1,5]naphthyridine-6,13-dione ethyl (2S,3aS,6S)-6-(3,3-dimethyl-2-oxobutyl)-2,3,3a,4,5,6-hexahydro-1H-indolo<3,2,1-de><1,5>naphthyridine-2-carboxylate ethyl (2S,3aS,6S)-6-(2-methyl-2-propenyl)-2,3,3a,4,5,6-hexahydro-1H-indolo<3,2,1-de><1,5>naphthyridine-2-carboxylate trans-11-methoxydeethyleburnamonine 3-benzyl-10-methoxy-1,2,3,3a,4,5-hexahydro-6H-indolo[3,2,1-de][1,5]naphthyridin-6-one 10-methoxy-6-oxo-6H-indolo[3,2,1-de][1,5]naphthyridine-3-oxide 4-methoxy-5-isobutoxycanthinone 3-methylcanthin-6-on-3-ium p-toluenesulfonate 6-methyl-5-phenyl-4H-indolo[3,2,1-de][1,5]naphthyridin-4-one (3aα,6β)-3-Benzyl-2,3,3a,4,5,6-hexahydro-1H-indolo<3.2.1-de><1.5>naphthyridin-6-ol 5-acetoxycanthin-6-one 3,4-diethyl-2,3,3a,4,5,6-hexahydro-6-oxo-1H-indolo(3,2,1-de)(1,5)-naphthyridine N-oxide-benzo[e]canthin-6-one